Eli Lilly and Company, Life for a Child and Beyond Type 1 Advance Partnership to Improve Diabetes Care in Resource-Limited Countries
January 28, 2021 at 01:00 pm
Share
To address inequity in access to quality diabetes care for many children and young adults around the world, Eli Lilly and Company and Life for a Child (LFAC) are significantly expanding their long-term partnership and shared mission to provide free immediate care as well as build sustainable diabetes care models for vulnerable populations. Additionally, Life for a Child announced a new strategic partnership with Beyond Type 1, a global diabetes nonprofit focused on changing what it means to live with chronic illness. Starting in February 2021, the partners will expand access to care for youth with diabetes from approximately 23,000 in 2020 to approximately 150,000 in 65 countries over the next 10 years. The program also strives to improve outcomes in all countries that receive support. Type 1 diabetes management support includes access to mealtime and basal insulins, reusable pens, blood glucose monitoring, A1C testing and diabetes education. The expansion of the Life for a Child program is part of Lilly's social impact efforts and supports Lilly 30x30, the company's goal to improve access to quality health care for 30 million people living in settings with limited resources, each year, by 2030. The expansion builds on decades of Lilly's global health work to improve equitable access to diabetes care and medicines, including in Kenya, Mexico, South Africa, and the U.S.
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).